Technology transfer to developing countries has contributed significantly
to increasing vaccine supply, and increased access to many vaccines has
been documented. In several cases this technology transfer has also
resulted in lower prices of vaccines, but this is not always so. For several
basic (EPI) vaccines there is a risk that supply may soon outstrip demand,
and establishment of new manufacturers for these vaccines could be
counterproductive, potentially leading to some established manufacturers
leaving the market.